Hayder Saeed, MD, discusses how the mechanism of action of tafasitamab makes the therapy a potent cancer cell killer for patients with diffuse large B-cell lymphoma.
Hayder Saeed, MD
Advertisement
Articles by Hayder Saeed, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Poll Results Reveal Readers’ Top Abstracts at ASH 2025
2
FDA Approves Liso-Cel as First CAR T-Cell Therapy for Marginal Zone Lymphoma
3
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
4
Lurbinectedin Contributes to Maintenance of Response in ES-SCLC
5
